Dupixent drives sales advancement in Sanofi's first quarter

Sanofi generated almost EUR 10bn in total sales during the year’s first three months. The French pharmaceutical firm gives several reasons why, one of which is a 45.7 percent growth of blockbuster drug Dupixent.
Photo: Charles Platiau/Reuters/Ritzau Scanpix
Photo: Charles Platiau/Reuters/Ritzau Scanpix
by christopher due karlsson, translated by daniel pedersen

Thursday, French pharmaceutical firm Sanofi has publicized its financial figures for the first quarter of the year, reporting that total sales in the first three months came to EUR 9.7bn.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading